Skip to content

Effects of cannabidiol in cannabis flower: Implications for harm reduction.

Laurel P Gibson, Hollis C Karoly, Jarrod M Ellingson, Jost Klawitter, Cristina Sempio, Julia E Squeri, Angela D Bryan, L Cinnamon Bidwell, Kent E Hutchison

Addiction biology January 1, 2022 DOI: 10.1111/adb.13092 via PubMed

Summary

AI-generated from the abstract

Cannabis flower with both THC and CBD produces similar positive effects but less paranoia and anxiety than THC-dominant cannabis. In a naturalistic at-home study, 159 regular cannabis users were randomly assigned to one of three chemovars: THC-dominant (24% THC, 1% CBD), THC+CBD (9% THC, 10% CBD), or CBD-dominant (1% THC, 23% CBD). Plasma samples showed those using the CBD-dominant or THC+CBD chemovars had significantly less THC and more CBD than those using the THC-dominant chemovar. The THC+CBD chemovar yielded similar positive subjective effects but significantly less paranoia and anxiety compared to the THC-dominant chemovar, suggesting potential harm reduction from CBD.

Study at a glance

Characteristics Randomized controlled trial Peer reviewed
Sample size 159
Population Regular cannabis users
Interventions THC+CBD CBD-dominant
Duration Before, immediately after, and 1 hour after ad libitum administration
Topics Cannabis CBD
Keywords Cannabinoids Subjective effects
Key finding THC+CBD chemovar produced similar positive subjective effects but significantly less paranoia and anxiety than the THC-dominant chemovar.

Abstract

Using a federally compatible, naturalistic at-home administration procedure, the present study examined the acute effects of three cannabis flower chemovars with different tetrahydrocannabinol (THC) to cannabidiol (CBD) ratios, in order to test whether chemovars with a higher CBD content produce different effects. Participants were randomly assigned to ad libitum administration of one of three chemovars (THC-dominant: 24% THC, 1% CBD; THC+CBD: 9% THC, 10% CBD; CBD-dominant: 1% THC, 23% CBD); 159 regular cannabis users (male = 94, female = 65) were assessed in a mobile pharmacology lab before, immediately after, and 1 h after ad libitum administration of their assigned chemovar. Plasma cannabinoids as well as positive (e.g., high, elation) and negative (e.g., paranoia and anxiety) subjective effects were assessed at each time points. Participants who used the CBD-dominant and THC + CBD chemovars had significantly less THC and more CBD in plasma samples compared to participants who used the THC-dominant chemovar. Further, the THC + CBD chemovar was associated with similar levels of positive subjective effects, but significantly less paranoia and anxiety, as compared to the THC-dominant chemovar. This is one of the first studies to examine the differential effects of various THC to CBD ratios using chemovars that are widely available in state-regulated markets. Individuals using a THC + CBD chemovar had significantly lower plasma THC concentrations and reported less paranoia and anxiety while also reporting similar positive mood effects as compared to individuals using THC only, which is intriguing from a harm reduction perspective. Further research is needed to clarify the harm reduction potential of CBD in cannabis products.

Explore topics

Comments

No comments yet.

Log in to comment